Available in United States, Argentina
A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate
efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in
patients with systemic lupus erythematosus (SIRIUS-SLE 2)
1Research sites
280Patients around the world